Nexalin Technology, Inc. (NXL)

Market Cap	42.24M
Revenue (ttm)	162,078
Net Income (ttm)	-5.55M
Shares Out	10.59M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,106
Open	3.870
Previous Close	3.890
Day's Range	3.830 - 4.160
52-Week Range	0.253 - 4.360
Beta	3.57
Analysts	Strong Buy
Price Target	3.00 (-24.82%)
Earnings Date	Nov 8, 2024

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The compan...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NXL
• Website: https://www.nexalin.com

Financial Performance

In 2023, Nexalin Technology's revenue was $110,748, a decrease of -91.62% compared to the previous year's $1.32 million. Losses were -$4.65 million, 173.8% more than in 2022.

Analyst Forecast

According to one analyst, the rating for NXL stock is "Strong Buy" and the 12-month stock price forecast is $3.0.

Price Target

$3.0

(-24.82% downside)

Analyst Consensus: Strong Buy